trial

The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial

NCTId NCT00468533
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Unknown
Enrollment 50 (estimated)
Sponsored by Yu-Li Hospital
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Unknown
Enrollment
50 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2006-05
Primary completion
—
Eligibility
ALL · 16 Years · 65 Years

Interventions & indications

Drugs
Aripiprazole

Sponsors

Yu-Li HospitalLead Sponsor

Investigators

1
Tsuo-Hung Lan, MD., PhD.Principal Investigator

Sites

1 total
Hualien City, Taiwan

Facts & assertions

3 sourced
Enrollment
50
Phase
PHASE4
Status
UNKNOWN
relationships
The graph out of here
drug
Aripiprazole
drug
lead_sponsor
Yu-Li Hospital
company
indication
Schizophrenia, Tardive Dyskinesia, Metabolic Syndrome
indication
Tardive Dyskinesia
indication
Schizophrenia
indication
investigator
Tsuo-Hung Lan, MD., PhD.
person